A total of 8-10 patients with hemophilia A will be recruited in the current study low dose emicizumab Thai hemophilia Thai hemophilia A
Conditions
Interventions
The parties have agreed to document their responsibilities and obligations with respect to the procedures for collecting, processing, evaluating, reporting and exchanging of safety information, in com
Prevention
Group 1
Sponsors
Division of Pediatric Hematology
Eligibility
Sex/Gender
Male
Age
24 Months to 45 Years
Inclusion criteria
Inclusion criteria: 1. Patients with moderate to severe hemophilia A (factor VIII activity less than 3%) with and without inhibitor. 2. Age 2 years or older 3. Patients are able to access to treatment for acute bleeding within 2 hours 4. Experienced low-dose prophylaxis or at least 5 bleeds in 6 months in episodic treatment
Exclusion criteria
Exclusion criteria: 1. Other coagulation disorders 2. Liver or renal diseases 3. Conditions that may increase risk of bleeding 4. Concomitant disease, condition or abnormality that could interfere with study conduct or pose unacceptable risk to patients 5. Required elective surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bleeding rate before and one year counting | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of life before, 3 ,6,9 and 12 months score | — |
Countries
Thailand
Contacts
Public ContactAmpaiwan Chuansumrit
Ramathibodi Hospital
Outcome results
None listed